Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer

Extended adjuvant endocrine therapy (10 vs. 5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer; however, the absolute benefit is modest, and toxicity and tolerability challenges remain. Predictive and prognostic information from genomic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanft, Tara, Aktas, Bilge, Schroeder, Brock, Bossuyt, Veerle, DiGiovanna, Michael, Abu-Khalaf, Maysa, Chung, Gina, Silber, Andrea, Hofstatter, Erin, Mougalian, Sarah, Epstein, Lianne, Hatzis, Christos, Schnabel, Cathy, Pusztai, Lajos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661200/
https://www.ncbi.nlm.nih.gov/pubmed/26578401
http://dx.doi.org/10.1007/s10549-015-3631-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661200/
https://www.ncbi.nlm.nih.gov/pubmed/26578401
http://dx.doi.org/10.1007/s10549-015-3631-9

Ejemplares similares